公司資料
Atara Biotherapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- ATRA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
8.36 USD (+3.34%)
收盤價
最後更新: 2026年8月17日
89.2M USD
市值
股價為何變動
As of Aug 17, 2026, ATRA closed up 3.34% at $8.36. No new same-company headline was identified in the current news window.
公司概覽
Allogeneic EBV T-Cell Platform
Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing.
Tabelecleucel
Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The U.S. application is supported by the pivotal single-arm ALLELE study.
Partnered Regulatory Model
Pierre Fabre Pharmaceuticals controls the U.S. regulatory and commercial program. Atara supports the BLA resubmission and retains eligibility for an approval milestone, commercial milestones, and tiered royalties.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。